Special Issue

Novel Insights into Diagnosis and Therapy of Advanced Renal Cell Carcinoma

Message from the Guest Editor

Renal cell carcinoma (RCC) is the most common type of kidney cancer, and in recent years, there has been a growing interest in identifying tumor markers not only for diagnostic purposes but also to improve the predictive power of clinical and pathological parameters. The treatment landscape for advanced or metastatic RCC is rapidly evolving, with risk stratification being a crucial step in developing a treatment plan. Cytoreductive nephrectomy (CN) and surgical metastasectomy are still considered fundamental treatments in selected cases after evaluation by a multidisciplinary team. However, recent studies have shown that CN may not always be necessary, especially with the availability of systemic therapies like immune checkpoint inhibitor-based combinations that have shown superior outcomes compared to monotherapy with tyrosine kinase inhibitors. This Special Issue of *Biomedicines* is dedicated to studies exploring the application of different approaches to understand the alterations in biological systems occurring in the pathogenesis of advanced RCC, as well as minimally invasive treatment and translational research for the diagnosis and management of this tumor.

Guest Editor

Prof. Dr. Giuseppe Lucarelli

Andrology and Kidney Transplantation Unit, Department of Emergency and Organ Transplantation—Urology, University of Bari "Aldo Moro", 70124 Bari, Italy

Deadline for manuscript submissions

closed (31 March 2025)

MDPI

Biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).